Abstract:Non–small cell lung cancer (NSCLC) is one of the leading causes of cancer related death worldwide. In recent years molecular characterisation of NSCLC has led to the identification of several driver events including EGFR constitutive activation, ALK-rearrangement and ROS1 fusion. Whilst there are several mechanisms of EGFR-mutation stated in the literature, how genomic heterogeneity related with acquired EGFR resistance to second targeted agent affects response to subsequent therapy has not been noted. We studied EGFR-TKI, gefitinib, in an EGFR 19 deleted lung adenocarcinoma patient to assess whether tissue and liquid biopsy could be integrated with radiologic imagings to demonstrate the impact of individual actionable driver mutation on lesion specific response. A 60-year old female, with no previous or family history of malignancy initially presented with EGFR 19 deletion mutation, ROS1 fusion negative and ALK rearrangement negative stage IV, T2aN3M1a lung adenocarcinoma detected in primary lung cancer tissue at the first diagnosis. Biopsy of this patient's metastatic right cervical lymph node following prolonged response to gefitinb led to the loss of detection of EGFR mutation, and the novel mechanism of acquired resistance with EZR-ROS1 fusion where crizotinib was demonstrated to have good efficacy in all lesions, especially the enlarged lymphadenopathy, and also including diminishing efficacy on metastatic brain lesions. In circulating tumor DNA (ctDNA), mutant EGFR levels disappeared followed by gefitinib treatment, and a recognized EZR-ROS1 fusion was meanwhile identified before crizotinib therapy. This case displays tumor heterogeneity in action, where targeted therapy selects against primary drivers, allowing for the establishment of sub-colonies with new drivers within the specific lesion. Parallel analysis of tumor biopsies when disease progressed and ctDNA monitoring showed that lesion specific radiographic responses to subsequent targeted therapies could be driven by district resistant mechanism in the separate tumor lesions within the same patient. This demonstrates that the importance of molecular heterogeneity surveillance ensuing from acquired resistance in managing NSCLC, and the usage of liquid biopsies to allow for a holistic viewpoint of the molecular landscape of this heterogeneous disease.

A case report of loss of thyroid transcription factor 1 expression in lung adenocarcinoma EBUS FNA

Nkx2-1: a Novel Tumor Biomarker of Lung Cancer

Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas

Non‐small cell lung carcinoma with focal coexpression of thyroid transcription factor‐1 and Δ Np63/p40: A case report

Expression of Telomeric Repeat Binding Factor 1 in Non-Small Cell Lung Cancer.

The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms

The Prognostic Value of TTF-1/NKX2-1 in Lung Squamous Cell Carcinoma

TTF-1 and EGFR Expression Are Related to EGFR Mutation in Lung Adenocarcinoma

The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas

Expression landscapes in non-small cell lung cancer shaped by the thyroid transcription factor 1.

Thyroid transcription factor 1 (TTF‐1) negativity as a predictor of unfavorable response to EGFR‐TKI therapy in advanced lung adenocarcinoma patients with EGFR mutations

TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities

Abnormal Expression and Clinical Significance of Telomeric Repeat Binding Factor 1 and Tankyrase 1 in Non-small Cell Lung Cancer

Non-small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours

P40 and TTF-1 double-expressing non-small cell lung cancer with EML4-ALK and PIK3CA gene mutations: A case report and review of the literature

Expression of thyroid transcription factor-1 in primary colorectal carcinoma and its metastases

GCDFP-15 positive and TTF-1 negative primary lung neoplasms: a tissue microarray study of 381 primary lung tumors

TLE1 Expression in NUT Carcinoma: A Case Report Highlighting a Potential Diagnostic Pitfall for the Pathologist

TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression

PS01.06: Tumor Heterogeneity in Lesion Specific Response Creates ROS1 Fusion Mediating Resistance to Gefitinib in EGFR 19 Deletion Lung Adenocarcinoma: Topic: Medical Oncology